On the 28th of July 2020, in the Official Journal of French Republic (JORF), an Order for the inclusion of the web application MOOVCARE POUMON intended for the medical telemonitoring of relapses and complications in patients with non-progressive lung cancer in the French List of Products and Healthcare Services Qualifying for Reimbursement (LPPR) was published. The application is already included in the LPPR list in section 1, “Materials and treatments in the home, dietary products, items for dressings,” chapter 1, section 7, and a specific sub-section 7, which has been created for web applications and software for remote monitoring.

The temporary reimbursement for telemedicine and digital care in all healthcare sectors has been extended by the Dutch Healthcare Authority (NZa) until December 31, 2020. In some sectors, the temporary extension will be converted into a structural extension by 2021.

In July 2020, new subsidy options for medical aids care at home became available within the Dutch program Good use of care at home (GGH). By funding research, the GGH program stimulates knowledge development about the quality, safety, effectiveness, and efficiency of innovative medical aids care at home. The deadline for submitting applications is 6 October 2020.

In July 2020, new material code and related conditions of reimbursement concerning the endoscopic treatment of primary or secondary vesicoureteral reflux were added to the List of reimbursable devices of the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV).

On the 9th of July 2020, the Ministry of Health of Spain released a screening guide for Hepatitis C infection as a part of the Strategic Plan for Addressing Hepatitis C in the National Health System. To improve access to screening and link to treatment monitoring, the guide proposes actions such as diagnosing the infection in a single step, training and support activities for health professionals, or a simplification of the models.

In July 2020, the Austrian Institute for Health Technology Assessment (AIHTA) published five decision support documents. The assessed technologies included implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure, intrauterine ultrasound-guided transcervical radiofrequency ablation, percutaneous transvascular implantation of a coronary sinus reducing stent, radiofrequency-induced intravesical chemohyperthermia for non-muscle invasive bladder cancer, and Vascular photodynamic therapy with Padeliporfin (Tookad® solution).

The German Association for Digital Health Care (Spitzenverband Digitale Gesundheitsversorgung e.V.) published the list of companies that submitted applications for inclusion in the directory of digital health apps (DiGA) in the first phase.

On July 03, 2020, the network of European HTA agencies, EUnetHTA, published the final report for the Rapid Relative Effectiveness Assessment OTCA24 ‘The 24-hour blood pressure measurement device Mobil-O- Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment.”

On behalf of the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether (former) heavy smokers within statutory health insurance (SHI) should be offered lung cancer screening using low-dose computed tomography (LDCT).

In July 2020, two new apps entered the level 1 of the mHealthBelgium validation pyramid. Healthentia is an eClinical platform to record Real World Data, that can be used either in clinical trials or by healthy individuals. Sunrise (class IIa) sleep testing device allows rapid and at home diagnosing respiratory sleep disorders.

The Clinical Coding and Schedule Development (CCSD) group develops and maintains procedural and diagnostics nomenclature for private payers in England. New procedure codes concern planning, insertion, and removal of high/low dose rate radioactive treatment (brachytherapy) into a prostate tumor, open/laparoscopic repair of Spigelian hernia, and others. The codes are introduced with a recommended adoption date being the 1st of August 2020. The document also contains a list of textual changes in codes and unacceptable combinations. There were no changes to the CCSD Schedule of Diagnostic Tests.